New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, # 2/3 - June-July, 1996

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
PROSTATE CANCER - PART II
Research Funding Sources 302
Update on Treatment Trends 302
Hormonal Therapies 303
  Hormonal Manipulation Options 303
    Luteinizing hormone-releasing hormone (LHRH) agonists 303
    Antiandrogens 303
  Hormonal Ablation Therapy 303
    Maximal androgen blockade 306
    Side effects 306
    Costs 306
  New Hormonal Therapies 306
    Alza 306
    Asta Medica 306
    Boehringer Ingelheim 306
    Janssen Pharmaceutica Research Institute 307
    Ligand 307
    Organon 307
    Pharmacia & Upjohn 307
Current Therapeutic Approaches for Locally Advanced and Late-stage Prostate Cancer 307
  Treatment of Locally Advanced Prostate Cancer 307
    Schering-Plough 307
  Treatment of Metastatic Prostate Cancer 309
  Treatment of Recurrent and Hormone-Refractory Prostate Cancer 309
    Immunex 309
    Parke-Davis 310
    British Biotech 310
Adjuvant and Combination Therapies 310
  Adjuvant Therapy Post Surgery/Radiotherapy 310
  Chemotherapy and Combination and Multimodality Therapies in Advanced Disease 310
Bone Pain Palliation 310
  Amersham International 311
  Mallinckrodt 311
  Cytogen 311
  Diatide 311
Novel Drugs in Development 311
  Identification of Genes Implicated in Prostate Cancer 312
    Centocor 312
    Genset 312
    LXR Biotechnology 312
    Millennium Pharmaceuticals 319
    Sequana Therapeutics 320
  Tissue-Targeted Toxic Therapy 320
  Immunotherapy/Vaccines 320
    Aphton Corporation 320
    Avigen 321
    CEL-SCI 321
    Cellcor 321
    Cytel 321
    Medarex 322
    Jenner Technologies 323
    Proteus Molecular Design 323
    Somatix Therapy 323
    Therion Biologics 323
    United Biomedical 323
  Immunotoxins 324
    Prizm Pharmaceuticals 324
  Natural Products 324
    Carrington Laboratories 324
    Paracelsian 325
    University of Wisconsin 325
  Other Drug Therapies 325
    Cephalon 325
    Elan 325
    Harrier 326
    Ilex Oncology 326
    ImClone Systems 326
    The Immune Response Corporation 326
    Matrix Pharmaceuticals 326
    Pherin 327
    Sheffield Medical Technologies 327
    UroCor 327
MEETING COVERAGE
NEW DEVELOPMENTS IN THE TREATMENT OF ADVANCED MULTIPLE COLORECTAL CANCER
From the 32nd Annual Meeting of the American Society of Clinical Oncology
Philadelphia, PA - May 18-21, 1996
5-Fluorouracil Combinations 328
  5-Fluororacil and Leucovorin Calcium 328
  5-Fluororacil and Folinic Acid 328
  5-Fluororacil and Trimetrexate 329
  5-Fluororacil and Azidothmidine (AZT, zidovudine) 329
  5-Fluororacil and 776C85 329
Irinotecan 330
  5-Fluororacil and Irinotecan Combinations 329
ZD1694 330
Oxaliplatin 330
  5-Fluororacil and Oxaliplatin 329

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887